Tempus AI EVP Erik Phelps sells $96,391 in inventory

CHICAGO—Erik Phelps, Government Vice President and Chief Administrative and Authorized Officer at Tempus AI, Inc. (NASDAQ:TEM), not too long ago offered 2,396 shares of the corporate’s Class A Frequent Inventory. The transaction, which befell on December 16, was valued at roughly $96,391, with a weighted common sale value of $40.23 per share. Since then, TEM shares have declined considerably, presently buying and selling at $34.30, reflecting broader market strain that has seen the inventory drop over 7% up to now week.

In keeping with the submitting, the sale was not discretionary. It was performed to cowl statutory tax withholding obligations associated to the vesting of restricted inventory items, a course of mandated by Tempus AI’s fairness incentive plans. Following this transaction, Phelps retains possession of 220,596 shares within the firm, representing a stake within the $6.13 billion market cap firm. InvestingPro information reveals the corporate maintains wholesome liquidity with a present ratio of two.69, whereas attaining robust income progress of 32% within the final twelve months.

The shares have been offered in a number of transactions, with costs starting from $40.00 to $40.56. Phelps has dedicated to offering detailed data on the person transaction costs upon request. For deeper insights into TEM’s insider buying and selling patterns and complete monetary evaluation, buyers can entry further InvestingPro metrics and professional suggestions.

In different current information, Tempus AI has been within the highlight with important developments. Following the corporate’s current earnings report, Piper Sandler elevated the inventory’s value goal from $40 to $70, sustaining a Impartial ranking. Stifel downgraded Tempus AI’s inventory from Purchase to Maintain, but raised the value goal to $65, whereas Needham elevated its value goal to $56 and maintained a Purchase ranking. These changes adopted Tempus AI’s acquisition of Ambry Genetics, a strategic transfer that doubtlessly introduces speedy genomics capabilities.

Tempus AI additionally fashioned a strategic partnership with Avacta Therapeutics to make use of AI in advancing oncology drug improvement, offering Avacta entry to Tempus’s complete multimodal datasets. As well as, Tempus AI’s Tempus ECG-AF gadget, which makes use of synthetic intelligence to establish sufferers at greater danger of atrial fibrillation/flutter, not too long ago acquired FDA clearance.

These are the most recent developments for Tempus AI. The corporate’s CEO, Eric Lefkofsky, has deferred the settlement of roughly 4.47 million restricted inventory items to a interval between January 15, 2025, and March 15, 2025. Tempus AI has additionally invested $36 million in Personalis (NASDAQ:PSNL), Inc., buying shares and exercising warrants for added inventory. These current actions and strategic strikes place Tempus AI for potential future progress, in accordance with analyst agency Needham.

This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.